• Earlier this week, Eli Lilly reported Phase 3 TRIUMPH-1 results showing its investigational obesity drug retatrutide delivered large, durable weight loss and cardiometabolic improvements in adults with obesity or overweight and at least one weight-related condition.
• The scale of weight reduction at higher doses, approaching outcomes typically associated with bariatric surgery, highlights how retatrutide could reshape expectations for drug-based obesity treatment if ultimately approved.
• We'll now examine how retatrutide's near‑surgical weight loss profile may influence Eli Lilly's existing investment narrative around obesity leadership.

Outshine the giants: these 14 early-stage AI stocks could fund your retirement.

Eli Lilly Investment Narrative Recap

To own Eli Lilly today you need to believe its incretin-based obesity and diabetes platform can support premium pricing and high growth while regulators, payers, and competitors push back. Retatrutide’s near surgical Phase 3 weight loss profile reinforces Lilly’s near term obesity leadership and could become a key incremental catalyst, but it also sharpens the main risk: concentrated dependence on a few obesity assets at a time when pricing pressure and reimbursement decisions are increasingly influential.

Among recent announcements, the strong maintenance data for Zepbound and Foundayo (orforglipron) is especially relevant here. Together with retatrutide, these results underline how Lilly is building a multi-product obesity franchise, from injectable induction to oral maintenance, that could deepen its market share but also raise exposure to any future policy-driven price cuts or payer restrictions that affect the entire class.

Yet behind the upbeat headlines, investors should still weigh how concentrated GLP 1 dependence and payer pushback could...

Eli Lilly's narrative projects $106.9 billion revenue and $42.9 billion earnings by 2029.

Uncover how Eli Lilly's forecasts yield a $1209 fair value, a 14% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts already assumed Lilly could lift annual revenue to about US$124.5 billion and earnings to roughly US$50 billion, so retatrutide’s data may either support that bullish view or force a rethink depending on how you see pricing and payer risks evolving.

Explore 21 other fair value estimates on Eli Lilly - why the stock might be worth 16% less than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Eli Lilly research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Eli Lilly research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Eli Lilly's overall financial health at a glance.

Contemplating Other Strategies?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Uncover the next big thing with 25 elite penny stocks that balance risk and reward.
• The future of work is here. Discover the 35 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.